SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s antibody discovery services.

“Bispecific antibodies have emerged as one of the most promising therapeutic modalities, validated both clinically and commercially, with the ability to unlock new mechanisms of action. This is exemplified in that the development of this class of biological therapeutic is growing at an accelerated pace compared to more standard monospecific approaches,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “Licensing the B-Body platform gives us direct access to a proven and scalable bispecific antibody platform that complements our current service offerings and further solidifies our position at the forefront of enabling next-generation biologics discovery for our customers, whether through traditional methods or AI-enabled.”

The B-Body platform expands and complements Twist’s current antibody discovery services as well as giving customers the plug-and-play flexibility to utilize their own pre-existing monospecific antibodies in the B-Body platform. With a comprehensive offering spanning in vivo, in vitro and AI-enabled discovery methods combined with high throughput antibody expression and characterization capabilities, and now adding on a powerful bispecific technology, Twist meets customers’ needs whether they are utilizing Twist’s biologics discovery capabilities, using Twist as a wet lab partner or training a large language model (LLM).

“The B-Body platform is designed to overcome multiple challenges commonly faced by bispecifics by enabling extremely favorable and predictable developability characteristics as well as at high concentrations with low viscosity needed for subcutaneous delivery,” said Roland Green, Ph.D., CEO and chairman of Invenra. “By licensing our B-Body technology to Twist, we leverage their expertise and infrastructure to enable broad access to the platform to support the rapidly growing demand for the development of next-generation bispecifics that address unmet medical needs for a breadth of diseases.”